Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mereo BioPharma Group plc - Sponsored ADR (MREO : NSDQ)

• Company Description    Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company's rare disease product candidates, setrusumab for the treatment of osteogenesis imperfecta and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease. Mereo BioPharma Group plc is based in LONDON. Number of Employees: 36

• Price / Volume Information    Yesterday's Closing Price: $0.34 Daily Weekly Monthly 20 Day Moving Average: 1,462,144 shares Shares Outstanding: 159.13 (millions) Market Capitalization: $53.93 (millions) Beta: 0.34 52 Week High: $3.05 52 Week Low: $0.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.20% -6.35% 12 Week -18.67% -14.05% Year To Date -18.67% -14.05%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE CAVENDISH PLACE FOURTH FLOOR - LONDON,X0 W1G 0QF GBR ph: 44-33-3023-7300 fax: - investors@mereobiopharma.com http://www.mereobiopharma.com

• General Corporate Information    Officers Denise Scots-Knight - Chief Executive Officer and Director Michael Wyzga - Chairman Christine Fox - Chief Financial Officer Jeremy Bender - Director Anders Ekblom - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 589492107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/12/26 Share - Related Items Shares Outstanding: 159.13 Most Recent Split Date: (:1) Beta: 0.34 Market Capitalization: $53.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.01 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.32 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - -83.02 09/30/25 - -74.96 06/30/25 - -80.00 ROA 12/31/25 - -72.68 09/30/25 - -63.73 06/30/25 - -66.94 Current Ratio 12/31/25 - 10.47 09/30/25 - 8.71 06/30/25 - 8.13 Quick Ratio 12/31/25 - 10.46 09/30/25 - 8.71 06/30/25 - 8.13 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - -8,375.60 09/30/25 - -8,314.60 06/30/25 - -9,910.00 Book Value 12/31/25 - 0.26 09/30/25 - 0.29 06/30/25 - 0.34 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©